Amyloid Beta and Transition Metals: Structure and Reactivity

Principal Investigator
Veronika Szalai, PhD
University of Maryland Baltimore County
Baltimore, MD, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2003 - March 31, 2006
Grant ID
A2003227
Summary
The diagnosis of Alzheimer’s disease (AD) is determined by the appearance of neuro-fibrillary tangles and amyloid plaques in brain tissue. Amyloid plaques are composed of repeating units of the protein amyloid-beta (Aß). While the global structure of amyloid plaques has to a great extent been revealed, local structural factors are not well understood. Transition metal ions like copper, zinc and iron have been observed to both increase and decrease the rate of Aß aggregation in vitro. The transition metals may not play an exclusively structural role in the biochemistry of Aß. The levels of copper ions are increased in the vicinity of amyloid plaques, yet decreased overall in AD-affected brains, implying that transition metal ion homeostasis is affected during the progression of the disease. The finding that transition metal ion levels in brains from AD patients are different from the levels in control samples has led researchers to investigate metal ion involvement in the neurotoxic events. In the presence of Aß in a test tube, some transition metals trap dioxygen to generate species that could potentially lead to neurodamage. The purpose of this study is to investigate the chemistry of metal ions in amyloid plaque neurotoxicity. Because a drug that binds metal ion has already been shown to dissolve amyloid plaques in vitro, the results could be helpful in designing new therapeutic strategies. If the mechanisms of the role of metal ions with Aß can be understood, Dr. Szalai’s team may be able to provide a promising new direction for drug design.
Grants
Related Grants
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD